Robin Lachapelle Exercises Options at ArriVent BioPharma Inc (AVBP) — SEC Form 4, Nov 02, 2026
SEC Form 4 · No Market Transaction
Option Exercise
Derivative exercise — no open market transaction.
Equity Position
571K sh
530,213 → 570,906
Equity Change
+7.7%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Robin Lachapelle CIK 0002009136 |
COO
|
Robin Lachapelle at ArriVent BioPharma Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at ArriVent BioPharma Inc
| 2026-02-05 | Award | — | View |
| 2025-07-15 | Exercise | — | View |
| 2025-02-14 | Award | — | View |
| 2024-09-23 | Exercise | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-30 | M - Exercise | 16,265 A | $3.65 | +$59,374 | 152,001 | Direct |
| Common Stock | 2026-10-30 | M - Exercise | 410 A | $2.28 | +$935 | 152,411 | Direct |
| Common Stock | 2026-10-30 | M - Exercise | 4,550 A | $2.28 | +$10,381 | 156,961 | Direct |
| Common Stock | 2026-10-30 | M - Exercise | 1,820 A | $2.28 | +$4,152 | 158,781 | Direct |
| Common Stock | 2026-10-30 | M - Exercise | 17,648 A | $6.24 | +$110,055 | 176,429 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2F3 | $2.28 | 2026-10-30 | M - Exercise | 410 D | $0.00 | 2031-09-07 | 410 Common Stock | Direct |
| Stock Option (right to buy)F2F4 | $2.28 | 2026-10-30 | M - Exercise | 4,550 D | $0.00 | 2032-01-31 | 4,550 Common Stock | Direct |
| Stock Option (right to buy)F2F4 | $2.28 | 2026-10-30 | M - Exercise | 1,820 D | $0.00 | 2032-01-31 | 1,820 Common Stock | Direct |
| Stock Option (right to buy)F2F5 | $3.65 | 2026-10-30 | M - Exercise | 16,265 D | $0.00 | 2033-01-31 | 16,265 Common Stock | Direct |
| Stock Option (right to buy)F2F6 | $6.24 | 2026-10-30 | M - Exercise | 17,648 D | $0.00 | 2033-08-21 | 17,648 Common Stock | Direct |
Non-Derivative Holdings
| Title | Shares Held | Ownership |
|---|---|---|
| Common StockF1 | 394,477 | Indirect by Trust |
Footnotes (6)
- F1
- The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust. Show more
- F2
- Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21. Show more
- F3
- The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Show more
- F4
- The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Show more
- F5
- The shares underlying this option vested as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Show more
- F6
- The shares underlying this option vested as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Show more
Related filings at ArriVent BioPharma Inc
Institutional Holders
13F holders · Jun 30, 2026
157
institutional managers reporting a position
Largest by reported value
5%+ Holders · 13D/G
8 filers
-
Orbimed Advisors Llc 5.8%
-
Black Rock, Inc. 6.8%
-
Fmr Llc 6.8%
Other insiders at ArriVent BioPharma Inc
GET /v1/forms/4/0001104659-26-121410
API docs
View Original SEC Filing